Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection

Liver International

Volumn 34, Issue 1, 2014, Pages 78-88

  Nishiguchi, Shuhei ^a   Sakai, Yoshiyuki ^a   Kuboki, Makoto ^b   Tsunematsu, Satoshi ^c   Urano, Yasuhisa ^d   Sakamoto, Wataru ^d   Tsuda, Yasuhiro ^d   Steinmann, Gerhard ^e   Omata, Masao ^f,g  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b University of Tokyo   (Japan)

^c KITASATO INSTITUTE HOSPITAL   (Japan)

^d NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f Yamanashi Prefectural Central Hospital   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

Author keywords

Faldaprevir; Genotype 1; Hepatitis C virus; Japanese

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FALDAPREVIR; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN;

ABDOMINAL DISCOMFORT; ADULT; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE JAUNDICE; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERBILIRUBINEMIA; INSOMNIA; JAPANESE; JAUNDICE; LOADING DRUG DOSE; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING;

FALDAPREVIR; GENOTYPE-1; HEPATITIS C VIRUS; JAPANESE;

ADULT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; JAPAN; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890126935     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12254     Document Type: Article

References (29)

1. World Health Organization. Hepatitis C Fact sheet N°164. 2012 Available at http://www.who.int/mediacentre/factsheets/fs164/en/index.html. Accessed 19 October 2012.
2. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011; 31 (Suppl. 2): 1-3.
3. Liu GG, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health 2012; 15: S65-71.
4. El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011; 53: 150-7.
5. Walter SR, Thein HH, Amin J, et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol 2011; 54: 879-86.
6. Sherman KE. Advanced liver disease: what every hepatitis C virus treater should know. Top Antivir Med 2011; 19: 121-5.
7. Walter SR, Thein HH, Gidding HF, et al. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol 2011; 26: 1757-64.
8. O'Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology 2008; 134: 1764-76.
9. Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterol Hepatol (N Y) 2011; 7: 661-71.
10. Yoshizawa H, Tanaka J, Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology 2006; 49: 7-17.
11. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010; 53: 39-43.
12. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73.
13. Japan Society of Hepatology. Treatment guidelines for chronic hepatitis C. Hep Research 2013; 43: 1-34.
14. Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
15. Okanoue T, Hayashi N, Tsubouchi H, et al. Telaprevir in combination with peginterferon alfa 2B and ribavirin therapy for genotype 1 chronic HCV patients: phase 3 study in Japan. Hepatology 2011; 54(Suppl. 1): 985A [Abstract No. 1330].
16. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
17. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
18. Ozeki I, Akaike J, Karino Y, et al. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. J Gastroenterol 2011; 46: 929-37.
19. INCIVEK™ (telaprevir) Highlights of US prescribing information. 2011 Available at http://pi.vrtx.com/files/uspi_telaprevir.pdf. Accessed 21 February 2012.
20. INCIVO™ (telaprevir) Summary of product characteristics. 2011 Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002313/WC500115529.pdf. Accessed 19 October 2012.
21. Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS 2011; 6: 514-26.
22. Llinas-Brunet M, Bailey MD, Goudreau N, et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). J Med Chem 2010; 53: 6466-76.
23. Manns MP, Bourliere M, Benhamou Y, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011; 54: 1114-22.
24. White PW, Llinas-Brunet M, Amad M, et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 2010; 54: 4611-8.
25. Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype-1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 2143-54.
26. Sulkowski MS, Bourliere M, Bronowicki JP, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57: 2155-63.
27. Broom C. Design of first-administration studies in healthy man. In: O'Grady J, Linet OI (eds), Early Phase Drug Evaluation in Man, London: MacMillan Press; 1990. p206-13.
28. Sane R, Podila L, Mathur A, et al. Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335. J Hepatol 2011; 54 (Suppl. 1): S488 [Abstract No. 1236].
29. Dieterich D, Asselah T, Guyader D, et al. SILEN-C3: treatment for 12 or 24 weeks with BI201335 combined with peginterferon alfa-2A and ribavirin (P.R) in treatment-naive patients with chronic genotype-1 HCV infection. Hepatology 2011; 54 (Suppl.): 378A [Abstract No. 36].